Nominally statistically significant associations of 2 SLC22A2 polymorphisms were observed : ( 1 ) with rs316019 at 6 months , overall ( [ c. 808T > G ; p.Ser270Ala ] , OR = 1.306 , 95 % CI = 1.034-1 .649 , p = .025 ) , and among those randomized to nicotine replacement therapy ( NRT ) ( OR = 1.784 , 95 % CI = 1.072-2 .970 , p = .026 ) ; and ( 2 ) with rs316006 ( c.1502-529A > T ) among those randomized to varenicline ( OR = 1.420 , 95 % CI = 1.038-1 .944 , p = .028 , OR = 1.362 , 95 % CI = 1.001-1 .853 , p = .04 ) at end of treatment and 6 months .